Support for this comes from the observation that KRAS G12V mutation is less abundant in colorectal adenocarcinomas than adenomas and the inverse correlations observed between KRAS G12V MF and maximum tumor dimension for both colon and thyroid cancers (Losi et al. 2009a; Parsons et al. 2010; Parsons and Myers 2013a). This evidence concerns the gene KRAS and thyroid gland carcinoma.